Last reviewed · How we verify

Dexamethasone+Tobramycin eye drop

Azienda USL Reggio Emilia - IRCCS · FDA-approved active Small molecule

Dexamethasone+Tobramycin eye drop is a Corticosteroid + aminoglycoside antibiotic combination Small molecule drug developed by Azienda USL Reggio Emilia - IRCCS. It is currently FDA-approved for Bacterial ocular infections with inflammation, Post-operative ocular inflammation and infection prophylaxis, Allergic conjunctivitis with secondary bacterial infection.

Dexamethasone reduces inflammation and immune response while tobramycin kills bacteria, providing combined anti-inflammatory and antibiotic effects in the eye.

Dexamethasone reduces inflammation and immune response while tobramycin kills bacteria, providing combined anti-inflammatory and antibiotic effects in the eye. Used for Bacterial ocular infections with inflammation, Post-operative ocular inflammation and infection prophylaxis, Allergic conjunctivitis with secondary bacterial infection.

At a glance

Generic nameDexamethasone+Tobramycin eye drop
SponsorAzienda USL Reggio Emilia - IRCCS
Drug classCorticosteroid + aminoglycoside antibiotic combination
TargetGlucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Dexamethasone is a corticosteroid that suppresses inflammatory cytokines and immune cell infiltration in ocular tissues. Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Together, they address both infectious and inflammatory components of ocular disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexamethasone+Tobramycin eye drop

What is Dexamethasone+Tobramycin eye drop?

Dexamethasone+Tobramycin eye drop is a Corticosteroid + aminoglycoside antibiotic combination drug developed by Azienda USL Reggio Emilia - IRCCS, indicated for Bacterial ocular infections with inflammation, Post-operative ocular inflammation and infection prophylaxis, Allergic conjunctivitis with secondary bacterial infection.

How does Dexamethasone+Tobramycin eye drop work?

Dexamethasone reduces inflammation and immune response while tobramycin kills bacteria, providing combined anti-inflammatory and antibiotic effects in the eye.

What is Dexamethasone+Tobramycin eye drop used for?

Dexamethasone+Tobramycin eye drop is indicated for Bacterial ocular infections with inflammation, Post-operative ocular inflammation and infection prophylaxis, Allergic conjunctivitis with secondary bacterial infection.

Who makes Dexamethasone+Tobramycin eye drop?

Dexamethasone+Tobramycin eye drop is developed and marketed by Azienda USL Reggio Emilia - IRCCS (see full Azienda USL Reggio Emilia - IRCCS pipeline at /company/azienda-usl-reggio-emilia-irccs).

What drug class is Dexamethasone+Tobramycin eye drop in?

Dexamethasone+Tobramycin eye drop belongs to the Corticosteroid + aminoglycoside antibiotic combination class. See all Corticosteroid + aminoglycoside antibiotic combination drugs at /class/corticosteroid-aminoglycoside-antibiotic-combination.

What development phase is Dexamethasone+Tobramycin eye drop in?

Dexamethasone+Tobramycin eye drop is FDA-approved (marketed).

What are the side effects of Dexamethasone+Tobramycin eye drop?

Common side effects of Dexamethasone+Tobramycin eye drop include Ocular irritation or discomfort, Transient blurred vision, Allergic reaction to tobramycin, Steroid-induced elevated intraocular pressure (with prolonged use).

What does Dexamethasone+Tobramycin eye drop target?

Dexamethasone+Tobramycin eye drop targets Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin) and is a Corticosteroid + aminoglycoside antibiotic combination.

Related